MANKIND
Mankind Pharma
Each stock's 10,000-path forecast, rendered as light.
Mankind Pharma (MANKIND) Stock Analysis & Case Study
Is MANKIND a good buy? The data-driven verdict.
Mankind Pharma (MANKIND) trades at ₹2,538,on the numbers it tread carefully, a Downstox Snapshot Score of 41/100.
On the numbers, Mankind Pharma (MANKIND) tread carefully, a Downstox Snapshot Score of 41/100, weighing expensive at 52.1× earnings, ROE of 13.1%, a 52% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
MANKIND fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is MANKIND overvalued? MANKIND P/E vs its Pharma
MANKIND's P/E of 52.1× sits above the Pharma peer median of 30.0×, so on earnings it screens richer than peers, while its 0.04% dividend yield is below the peer median of 0.51%.
MANKIND share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of MANKIND history (6%/yr drift, 29%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| MANKIND 2027 | ₹1,687 | ₹2,451 | ₹3,569 | +2% |
| MANKIND 2028 | ₹1,460 | ₹2,489 | ₹4,240 | +3% |
| MANKIND 2029 | ₹1,308 | ₹2,545 | ₹4,874 | +5% |
| MANKIND 2030 | ₹1,208 | ₹2,562 | ₹5,476 | +6% |
| MANKIND 2031 | ₹1,132 | ₹2,611 | ₹6,091 | +8% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability MANKIND goes up, or doubles?
The bull case for MANKIND
- A healthy 13.1% return on equity.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹4,874.
The bear case & risks
- A rich 52.1× P/E leaves a thin margin of safety if growth slows.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,308.
MANKIND volatility & expected range, how bumpy is the ride?
Over the last 2.0 years MANKIND compounded at 6%/year with annualized volatility of 29%. That volatility implies a 1-year 80% range of ₹1,687–₹3,569, the honest backbone behind any single price target.
MANKIND price forecast, the full 60-month probability fan
MANKIND price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds MANKIND hits common targets within the simulated horizon?
Full multi-horizon detail on the MANKIND price target & forecast page.
MANKIND Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. MANKIND scores 4/9,mixed financial health.
MANKIND MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy MANKIND with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 28.5% | 3.5× |
| Zerodha | 24.3% | 4.1× |
| DhanCHEAPEST | 23.0% | 4.3× |
Compare every broker on the MANKIND MTF page.
MANKIND vs peers,Pharma comparison
About Mankind Pharma: sector, index & market-cap context
Mankind Pharma (MANKIND) is a large-cap NSE-listed company in the Pharma sector, and a constituent of the Nifty 50 index group, with a market capitalisation of ₹1.05L Cr. See more Nifty 50 stocks.
How the MANKIND Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Mankind Pharma's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
MANKIND analysis, FAQs
Is Mankind Pharma (MANKIND) a good buy?
On the numbers, Mankind Pharma (MANKIND) tread carefully, a Downstox Snapshot Score of 41/100, weighing expensive at 52.1× earnings, ROE of 13.1%, a 52% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is MANKIND overvalued or undervalued?
MANKIND trades at 52.1× earnings versus a peer median of 30.0×, so it screens richer than its Pharma peers.
What is the MANKIND share price target for 2031?
MANKIND's probability-weighted 2031 median target is ₹2,611, with an 80% range of ₹1,132–₹6,091 (10,000-path Monte-Carlo).
What is the probability MANKIND doubles in 5 years?
The modelled probability of MANKIND reaching ₹4,828 (2×) within 5 years is 18%.
What is the bull case for MANKIND?
A healthy 13.1% return on equity.
What are the risks in MANKIND?
A rich 52.1× P/E leaves a thin margin of safety if growth slows.